THCV, or tetrahydrocannabivarin may have the potential to help with energy, focus/attention, and even appetite, weight/BMI, according to
InMed Pharmaceuticals Inc.’s
(NASDAQ: INM). In addition, according to LAweekly.com, THCV benefits are reported to be pretty incredible, including but not limited to: Appetite suppression, weight loss aid, Blood sugar regulation, Reducing muscular tremors and neuroprotection. “Neuroprotectants like THCV protect the neurological function of the brain by strengthening neural pathways and neurons, while stimulating neurogenesis, which is the birth of new neurons to keep brain functionality efficient,” added LAweekly.com. In addition to
InMed Pharmaceuticals,
companies such as
Tilray Inc.
(NASDAQ: TLRY) (TSX: TLRY),
Canopy Growth
(TSX: WEED) (NASDAQ: CGC),
Jazz Pharmaceuticals
(NASDAQ: JAZZ), and
AbbVie Inc.
(NYSE: ABBV) could benefit from the news.
InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector
InMed Pharmaceuticals Inc
., a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce it has launched B2B sales of the rare cannabinoid delta 9-dominant tetrahydrocannabivarin (“d9-THCV”) into the health and wellness sector via its wholly-owned subsidiary, BayMedica LLC (“BayMedica”).
“We are very excited to launch our highly anticipated d9-THCV and further enhance BayMedica’s growing product portfolio,” stated Shane Johnson, MD, SVP and General Manager of BayMedica. “THCV is one of the few rare cannabinoids that has been researched in early clinical trials for various therapeutic effects, fueling significant interest by end-product manufacturers and consumers alike. In anticipation of this launch, we have expanded internal sales and marketing infrastructure, developed new distribution channels and optimized the supply chain to ensure a consistent and reliable supply of a high-quality product. As this market continues to mature, we are well positioned to be a leading supplier of rare cannabinoids to the health and wellness industry. We currently have several high-value, rare cannabinoids in various stages of commercial development and will continue to expand our cannabinoid portfolio over the coming years”.
THCV – What is it and why the growing interest?
Although similar in name and structure to its intoxicating cousin THC, THCV has a slightly modified structure that leads to significantly different physiological effects, including being non-intoxicating. In addition, while THC is found abundantly in many strains of the
Cannabis
plant, THCV is a rare cannabinoid that is generally found in only trace amounts in the plant.
D9-THCV has been researched for a variety of physiological benefits, most notably for its appetite suppressing effects, making it a compelling compound for use in weight management. It has also attracted interest for its potential ability to help maintain normal blood sugar levels and has been studied for a myriad of other effects.
InMed is committed to developing products based on scientific evidence, and as previously announced, BayMedica has supplied d9-THCV to be evaluated in Radicle Science’s “Radicle Energy” study on energy, focus/attention, appetite and weight/body mass index (“BMI”). The study is being conducted to provide valuable third-party validation of the potential effects of d9-THCV.
Delta 9 vs. Delta 8 – An important differentiator
As compared to d8-THCV, d9-THCV is the naturally-occurring variant found in the
Cannabis
plant, has specifically been the subject of the vast majority of scientific research into the potential effects of THCV, and is significantly more difficult to manufacture. BayMedica manufactures a d9-dominant THCV to high purity via a proprietary process. BayMedica’s cannabinoids are made in accordance with food-grade GMP standards and are rigorously tested at certified laboratories. Like all BayMedica minor cannabinoid products, d9-THCV can be combined in precise ratios with other cannabinoids to create unique health and wellness products.
Commercial Opportunity – Increasing demand for rare cannabinoids
With the availability of these rare cannabinoids at commercial scale, product manufacturers and consumer brands now have the ability to deliver differentiated products, including augmenting existing CBD-based products, to consumers in the health and wellness marketplace. With flexibility across multiple manufacturing approaches, and its ability to scale up to meet market demand, BayMedica is well positioned to take advantage of this rapidly growing industry.
This emerging market is expected to grow significantly due to the increasing awareness of the potential benefits of cannabinoid-based products. According to the December 2021 Grand View Research report, the retail market for rare cannabinoids is expected to reach US$26 billion by 2028 with a forecasted compounded annual growth rate (CAGR) of >20% during the same period. [
U.S. Minor Cannabinoids Market Size Report, 2021-2028 (grandviewresearch.com)
]
For more information on how to purchase d9-THCV and other rare cannabinoids, please reach out to the BayMedica sales team at:
[email protected]
To learn more about d9-THCV:
Tetrahydrocannabivarin (THCV) | BayMedica
/
Learn more about InMed’s Cannabinoids in Development:
Other related developments from around the markets include:
Tilray Inc.
announced that its
medical cannabis brand, Aphria, has launched
CBN Night Oil
,
the brand’s first CBN oil medical product formulated for patients’ nighttime use. Blair MacNeil, President, Tilray Canada, said, “Tilray Medical is committed to providing patients in Canada and around the globe with safe, high-quality cannabinoid-based medicine. We are pleased to add a dedicated night oil to the Aphria medical portfolio and broaden our offering of effective medical cannabis products to patients with a wider range of needs.”
Canopy Growth
announced its
financial results for the fourth quarter
and fiscal year ended March 31, 2022. “Canopy Growth is building the industry’s leading portfolio of premium brands across North America. We’ve taken concrete steps to advance this ambition by strengthening our positioning in Canada, further adding two high performance brands to our portfolio with Wana Brands and Jetty Extracts, bolstering our U.S. THC ecosystem. In the fiscal year ahead, we will remain focused on growing our market share in the key segments that will drive profitable growth and continuing to scale our premium brands across North America,” says David Klein, Chief Executive Officer.
Jazz Pharmaceuticals
announced
financial results for the first quarter of 2022
, raised 2022 financial guidance and provided business updates. “We’re pleased to raise our top- and bottom-line guidance, driven by our continued execution and significant progress across commercial and R&D in the first quarter, which positions us well for the rest of the year and to achieve Vision 2025,” said Bruce Cozadd, chairman and CEO of Jazz Pharmaceuticals. “Our recent launches of Xywav
®
, in both narcolepsy and idiopathic hypersomnia (IH), and Rylaze
®
in acute lymphoblastic leukemia (ALL), continue to generate increased prescriber and patient adoption, and demonstrate our ability to deliver innovative new medicines to improve the lives of patients and their families. On the corporate development front, our three recent transactions are aligned with our broader strategy, allowing us to focus on our highest priorities, enhance our pipeline in areas of key interest in neuroscience and oncology and drive long-term shareholder value.”
AbbVie Inc.
announced it will present
data from its migraine portfolio
at the 2022 American Headache Society (AHS) Annual Scientific Meeting to be held in Denver, June 9-12. A total of 29 abstracts, including two oral presentations and one late-breaker presentation, will cover a wide range of studies across AbbVie’s migraine portfolio, and highlight the company’s newest migraine treatment, atogepant (QULIPTA). “As the only pharmaceutical company that offers three products that span the spectrum of migraine treatment, which include preventive therapies for chronic and episodic migraine and an acute treatment for migraine attacks, AbbVie is pleased to present new data across its migraine portfolio,” said Michael Gold, M.D., therapeutic area head, neuroscience development, AbbVie. “We continue to research potential new indications that may help more people living with this debilitating disease. Presenting robust data from our migraine portfolio demonstrates our commitment to people living with migraine and our goal of preserving personhood.”
Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. InMed Pharmaceuticals Inc. has paid three thousand five hundred dollars for advertising and marketing services to be distributed by Winning Media. Winning Media is only compensated for its services in the form of cash-based compensation. Winning Media owns ZERO shares of InMed Pharmaceuticals Inc.
Click
here for
disclaimer
.
Contact Information:
2818047972
[email protected]
